Analyst firms · Piper Sandler · CAPR
Piper Sandler CAPR price target and rating history
Capricor Therapeutics Inc. (CAPR) · Health Care
Piper Sandler rates Capricor Therapeutics Inc. (CAPR) Overweight with a $25 price target, as of its latest action on Sep 1, 2026. It has published 3 rating actions on CAPR since October 2024, including 1 upgrade and 1 downgrade. Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Piper Sandler's $25 is 9% above that.
- Current rating
- Overweight
- Price target
- $25
- Median target, all firms
- $23
- Actions on CAPR
- 3
Piper Sandler price target on CAPR
Every Piper Sandler rating on CAPR
- Sep 1, 2026
- Jul 30, 2026
- Oct 21, 2024
How other firms rate CAPR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| B. Riley Securities | Buy | $21 | Sep 14, 2026 |
| Piper Sandler | Overweight | $25 | Sep 1, 2026 |
| Oppenheimer | Outperform | $54 | Aug 25, 2026 |
| Cantor Fitzgerald | Overweight | $28 | Aug 14, 2026 |
| Maxim Group | Hold | Jul 30, 2026 | |
| H.C. Wainwright | Neutral | Jul 30, 2026 | |
| Ladenburg Thalmann | Neutral | Jul 30, 2026 | |
| Alliance Global Partners | Neutral | $7 | Jul 28, 2026 |
| Roth Capital | Neutral | $7 | Jul 27, 2026 |
Questions about Piper Sandler and CAPR
- What is Piper Sandler's price target for CAPR?
- Piper Sandler's latest stated price target for Capricor Therapeutics Inc. (CAPR) is $25, from its action on Sep 1, 2026.
- What is Piper Sandler's rating on CAPR?
- Piper Sandler rates CAPR Overweight, a bullish rating, as of Sep 1, 2026.
- When did Piper Sandler last change its view on CAPR?
- On Sep 1, 2026, Piper Sandler upgrades to Overweight from Neutral, price target $25.
- How does Piper Sandler's CAPR target compare with other analysts?
- Across 6 firms with a CAPR price target in the last 12 months, the median target is $23. Piper Sandler's $25 is 9% above that.
More CAPR rating histories
All Piper Sandler ratingsCAPR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.